Molecular Oncology · 2017 · 67 citations · 42 references
Life SciencesOncologyPharmacologyAutophagyMolecular OncologyMolecular PharmacologyApoptosis In CancerApoptosis RegulationApoptotic SignalingAutophagy In CancerCancer Cell SignalingProtein Kinase CascadesApoptosis Regulation By KinasesApoptosis Signaling In CancerApoptotic Signaling In CancerCancer Cell ApoptosisCdk ActivationHepatocellular Carcinoma PathogenesisHormone Receptor - Positive Breast CancerProtein Kinase Inhibitors
Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor-positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are under active investigation. Here, we report the effects and a novel mechanism of action of palbociclib in HCC. We found that palbociclib induced both autophagy and apoptosis in HCC cells through a mechanism involving 5' AMP-activated protein kinase (AMPK) activation and protein phosphatase 5 (PP5) inhibition. Blockade of AMPK signals or ectopic expression of PP5 counteracted the effect of palbociclib, confirming the involvement of the PP5/AMPK axis in palbociclib-mediated HCC cell death. However, CDK4/6 inhibition by lentivirus-mediated shRNA expression did not reproduce the effect of palbociclib-treated cells, suggesting that the anti-HCC effect of palbociclib is independent of CDK4/6. Moreover, two other CDK4/6 inhibitors (ribociclib and abemaciclib) had minimal effects on HCC cell viability and the PP5/AMPK axis. Palbociclib also demonstrated significant tumor-suppressive activity in a HCC xenograft model, which was associated with upregulation of pAMPK and PP5 inhibition. Finally, we analyzed 153 HCC clinical samples and found that PP5 expression was highly tumor specific and was associated with poor clinical features. Taken together, we conclude that palbociclib exerted antitumor activity against HCC through the PP5/AMPK axis independent of CDK4/6. Our findings provide a novel mechanistic basis for palbociclib and reveal the therapeutic potential of targeting PP5/AMPK signaling with a PP5 inhibitor for the treatment of hepatocellular carcinoma.
42
Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations
Medicine, Oncology, Pharmacology +17
AMPK Is a Direct Adenylate Charge-Regulated Protein Kinase
Jonathan S. Oakhill, Rohan Steel, Zhiping Chen et al. · Science · 2011 · 606 citations
Stephen Davies, Nicholas R. Helps, Philip Cohen et al. · FEBS Letters · 1995 · 602 citations